Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 9/20 | 0.60 |
| ▸ | MMP9 | P14780 | 9/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | MMP1 | P03956 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | APEX1 | P27695 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | MMP3 | P08254 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | HEXA | P06865 | 1/20 | 0.46 |
| ▸ | HEXB | P07686 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7073583 | 0.93 | MMP2 (0.56) | MMP2MMP9HSD17B10GAAMEN1 | |
| SCHEMBL7224275 | 0.86 | MMP2 (0.54) | MMP2MMP9GAAMEN1KMT2A | |
| SCHEMBL7231531 | 0.82 | MMP2 (0.59) | MMP2MMP9RAB9AMMP1NPC1 | |
| SCHEMBL8014995 | 0.81 | TP53 (0.46) | MMP2MMP9KMT2APOLBTDP1 | |
| SCHEMBL7231569 | 0.81 | MMP2 (0.53) | MMP2MMP9GAAMEN1KMT2A | |
| SCHEMBL7861661 | 0.81 | NPC1 (0.62) | MMP2MMP9HSD17B10GAAMEN1 | |
| SCHEMBL7077886 | 0.79 | MMP2 (0.66) | MMP2MMP9HSD17B10GAAMEN1 | |
| SCHEMBL7231210 | 0.79 | MMP2 (0.46) | MMP2MMP9GAAMEN1KMT2A | |
| SCHEMBL6380461 | 0.78 | MTNR1A (0.50) | KMT2ARAB9ANPC1ALDH1A1 | |
| SCHEMBL9113979 | 0.78 | RAB9A (0.69) | HSD17B10GAAMEN1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030207889-A1 | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity | OWEN DAVID ALAN (GB) | 2003-11-06 | — | — | US | disclosed |
| US-6566384-B1 | For therapy of cancer, inflammation and inflammatory diseases, tissue degeneration, periodontal disease, ophthalmological disease, dermatological disorders, fever, cardiovascular effects, haemorrhage, coagulation and acute phase response | DARWIN DISCOVERY LTD. (GB) | 2003-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207889-A1 | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity | MMP13, MMP2, MMP9 | MMP2 2/4885MMP9 3/4885HSD17B10 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.